Early clinical results from Episealer® Talus study presented at scientific congress
Episurf Medical (Nasdaq: EPIS B) today announces that clinical results for the Episealer® Talus technology have been presented at the 38[th] Congress of the Italian Foot and Ankle Society in Riva Del Garda, Italy, on September 21-22. The presentation with the title “Episealer Talus, an innovative patient-specific metallic implant for the treatment of osteochondral lesions of the talar dome” was held by Dr Marco Di Ponte from the Rizzoli Orthopedic Institute, Italy, and reported on early results from an investigator-initiated study. The study follows 20 patients who received an Episealer®